LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
SPRB
Spruce Biosciences, Inc.
There isn't enough reported data to score SPRB yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
SPRB Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Unavailable | |
| Unavailable |
SPRB's revenue and profitability are currently weak. There isn't enough data to rate its cash flow and balance sheet.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
SPRB PE Valuation
SPRB has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
SPRB Forward outlook
There aren't enough analyst estimates for SPRB to show an outlook.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over SPRB on earnings quality, reporting a profit while its opponent remains loss making.
SPRB Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$56.56 | +$29.02 |
| Q2 2026 | -$62.63 | +$24.12 |
| Q1 2026 | -$59.45 | +$40.30 |
| Q4 2025 | -$74.51 | +$22.24 |
| Q3 2025 | -$85.58 | -$15.83 |
| Q2 2025 | -$86.75 | -$10.25 |
| Q1 2025 | -$99.75 | -$15.75 |
| Q4 2024 | -$96.75 | -$3.75 |
SPRB is still losing money, but far less than before: $56.56 per share over the past year, against $147.00 at its worst in late 2022.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the stronger quarterly revenue trend. Revenue is up 39% for LLY versus down 100% for SPRB.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY's operating margin was 34% last quarter, down 6.6 points from the same quarter a year ago.
SPRB Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2024 | $697K | -76% |
| Q3 2024 | $602K | -80% |
| Q2 2024 | $1.6M | -26% |
| Q1 2024 | $2M | +1.9% |
SPRB's revenue has slid since its 2023 peak: $0 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2024 | -3454% | -3067 points |
| Q3 2024 | -1563% | -1118 points |
| Q2 2024 | -623% | +22 points |
| Q1 2024 | -631% | +41 points |
| Q4 2023 | -387% | N/A |
| Q3 2023 | -444% | N/A |
| Q2 2023 | -645% | N/A |
| Q1 2023 | -672% | N/A |
SPRB's operating margin was −3454% last quarter, down 3067 points from the same quarter a year ago, near the bottom of its range since 2023.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over SPRB on cash generation, producing positive trailing cash flow while its opponent burns cash.
SPRB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$13.8M | -$8.4M |
| Q2 2026 | -$22.3M | -$13.4M |
| Q1 2026 | -$8.7M | +$4M |
| Q4 2025 | -$6.5M | +$14.2M |
| Q2 2025 | -$8.8M | +$2.3M |
| Q1 2025 | -$12.7M | +$2.2M |
| Q4 2024 | -$20.7M | -$9.5M |
| Q1 2024 | -$15M | -$3.2M |
SPRB has burned cash in almost every quarter: −$51M over the past year, against −$48M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over SPRB on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
SPRB Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +16% | +390K shares |
| 1 year | +377% | +2.2M shares |
| 3 years | +422% | +2.3M shares |
| 5 years | +809% | +2.5M shares |
SPRB has 3M diluted shares, up 377% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2020 | — |
| Q1 2020 | — |
| Q4 2019 | — |
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
SPRB Net Leverage
SPRB's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
SPRB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.0 | Neutral |
| Stochastic | 27.3 | Neutral |
SPRB's weekly RSI is 42 (neutral) and its Stochastic is 27 (neutral).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
SPRB PE vs Healthcare Sector
SPRB has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over SPRB on trend strength, trading above more of its moving averages.
SPRB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $44.9 | 4.5% below |
| 20 week MA | $48.4 | 11% below |
| 50 week MA | $58.4 | 27% below |
| 100 week MA | $45.9 | 6.5% below |
| 200 week MA | $86.6 | 50% below |
SPRB is in a downtrend: it's below all five of its weekly moving averages, and 50% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over SPRB on returns for 2026, with the stronger performance.
SPRB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $1,275.0 | $1,868.3 | +47% |
| 2021 | $1,868.3 | $279.0 | -85% |
| 2022 | $279.0 | $81.0 | -71% |
| 2023 | $81.0 | $219.8 | +171% |
| 2024 | $219.8 | $32.9 | -85% |
| 2025 | $32.9 | $85.7 | +161% |
| 2026 YTD | $85.7 | $42.9 | -50% |
SPRB's yearly returns have swung widely, from +171% in 2023 to −85% in 2021. It's down 50% so far in 2026.